
Paul Milne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6356766/publications.pdf Version: 2024-02-01



ΔΑΙΠ ΜΠΝΕ

#	Article	IF	CITATIONS
1	Cellular distribution of mutations and association with disease risk inÂLangerhans cell histiocytosis without <i>BRAF</i> V600E. Blood Advances, 2022, 6, 4901-4904.	5.2	4
2	Epigenetic regulator genes direct lineage switching inÂ <i>MLL/AF4</i> leukemia. Blood, 2022, 140, 1875-1890.	1.4	26
3	Notch-Mediated Generation of Monocyte-Derived Langerhans Cells: Phenotype and Function. Journal of Investigative Dermatology, 2021, 141, 84-94.e6.	0.7	10
4	Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia, 2021, 35, 3299-3303.	7.2	18
5	Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans. Immunity, 2020, 53, 353-370.e8.	14.3	146
6	Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Advances, 2020, 4, 87-99.	5.2	25
7	Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. Journal of Clinical Oncology, 2019, 37, 2857-2865.	1.6	132
8	OP0202â€EFFECT OF RSLV-132 ON FATIGUE IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME – RE PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY. , 2019, , .	SULTS OF	A ₃
9	AB0184â€FLOW CYTOMETRIC IMMUNOPHENOTYPING OF SALIVARY GLANDS IN PRIMARY SJÖGREN'S SYNDROME. , 2019, , .		15
10	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances, 2019, 3, 3052-3061.	5.2	15
11	Biallelic interferon regulatory factor 8 mutation: AÂcomplex immunodeficiency syndrome with dendritic cell deficiency, monocytopenia, and immune dysregulation. Journal of Allergy and Clinical Immunology, 2018, 141, 2234-2248.	2.9	63
12	Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances, 2018, 2, 1157-1169.	5.2	28
13	Targeted treatment of brainstem neurohistiocytosis guided by urinary cell-free DNA. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e299.	6.0	7
14	Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood, 2017, 130, 167-175.	1.4	136
15	Langerhans cell origin and regulation. Current Opinion in Hematology, 2016, 23, 28-35.	2.5	78
16	LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. Journal of Immunology, 2016, 196, 2085-2094.	0.8	49
17	Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model. Blood, 2016, 128, 4031-4031.	1.4	Ο

18	CD1c+ blood dendritic cells have Langerhans cell potential. Blood, 2015, 125, 470-473.	1.4	72

PAUL MILNE

#	Article	IF	CITATIONS
19	Langerin-expressing dendritic cells in human tissues are related to CD1c+ dendritic cells and distinct from Langerhans cells and CD141high XCR1+ dendritic cells. Journal of Leukocyte Biology, 2015, 97, 627-634.	3.3	105
20	Human Dermal CD14 + Cells Are a Transient Population of Monocyte-Derived Macrophages. Immunity, 2014, 41, 465-477.	14.3	256
21	The evolution of cellular deficiency in GATA2 mutation. Blood, 2014, 123, 863-874.	1.4	189
22	Prognostic significance of immunohistochemistryâ€based markers and algorithms in immunochemotherapyâ€ŧreated diffuse large <scp>B</scp> cell lymphoma patients. Histopathology, 2013, 63, 788-801.	2.9	25
23	Differential IRF8 Requirement Defines Two Pathways of Dendritic Cell Development in Humans. SSRN Electronic Journal, 0, , .	0.4	7